Therapeutic: electrolyte modifiers
Pharmacologic: phosphate binders
Reduction of serum phosphate levels in patients with hyperphosphatemia associated with end-stage renal disease.
A polymer that binds phosphate in the GI tract, preventing its absorption. Therapeutic Effects: Decreased serum phosphate levels and reduction in the consequences of hyperphosphatemia (ectopic calcification, secondary hyperparathyroidism with osteitis fibrosa).
Adverse Reactions/Side Effects
GI: diarrhea, dyspepsia, vomiting, constipation, flatulence, nausea.
PHYSICAL THERAPY IMPLICATIONS
Implement therapeutic exercises (resistive training, aerobic exercises, gait training) as tolerated to complement the effects of drug therapy and help maintain function in patients with end-stage renal disease.
Advise patient about the likelihood of GI reactions such as nausea, vomiting, diarrhea, constipation, indigestion, and flatulence. Instruct patient to report severe or prolonged GI problems.
Absorption: Not absorbed; action is local (in GI tract).
Metabolism and Excretion: Eliminated in feces.
TIME/ACTION PROFILE (decrease in serum phosphate levels)
|ROUTE ||ONSET ||PEAK ||DURATION |
Contraindicated in: Hypersensitivity; Hypophosphatemia; Bowel obstruction.
Use Cautiously in: Dysphagia, swallowing disorders, severe GI motility disorders, or major GI tract surgery; OB/Lactation/Pedi: Safety not established.
Drug-Drug: Concurrent anticonvulsants or antiarrhythmics; sevelamer may affect absorption; administer 1 hr before or 3 hr after. May ↓ absorption of other drugs and ↓ effectiveness, especially drugs whose efficacy is dependent on tightly controlled blood levels.
PO (Adults): 800–1600 mg with each meal.